ANTI-FIBROSIS COMPOUND

Fibrosis continues to threaten human health in multiple organs, including lung, kidney, and liver. Recently findings that by decreasing MDM4 protein myofibroblasts have reduced viability in lungs, causing a reduction in fibrosis. We have engineered a plate assay yielding massive collagen induction in a TGF-beta dependent reaction, creating a new model for scarring/fibrosis. This model can be used to test for MDM4 involvement, as well as for identification of other key players. Classic anti-fibrosis compounds screened using our fibrosis model showed some effectiveness, and also identified one strong agonist. We offer our novel fibrosis assay for use in screening for anti-fibrotic lead compounds. 

Slide3.JPG